Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.028 -0.062 (-2.98%)
Streaming Delayed Price Updated: 10:32 AM EST, Dec 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
38 39 Next >
Global Cancer Therapy Market Expected to Reach $268 Billion In 2026, With A CAGR Of 9.15%
Palm Beach, FL –November 16, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic has affected the healthcare systems globally and also has a significant impact on the cancer therapy... 
Via FinancialNewsMedia
News headline image
NASDAQ:SAVA Long Term Investor Notice: Investigation of Potential Wrongdoing at Cassava Sciences, Inc. ↗
San Diego, CA -- (SBWIRE) -- 11/15/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Cassava Sciences, Inc.. 
Via SBWire
Topics Lawsuit
News headline image
Cassava Pops As Cortexyme Dives — Why One Alzheimer's Stock Is 'Back On Track' ↗
An analyst says Cassava is on track, but Cortexyme took another beating Thursday. 
Via Investor's Business Daily
News headline image
7 Short-Squeeze Stocks Loaded With High-Risk, High-Reward Upside ↗
Here are seven of the top short-squeeze stocks investors may want to keep their eye on, as retail investors lay and wait for the next squeeze. 
Via InvestorPlace
News headline image
Cassava Sciences Needs Time and Data to Prove Itself Before You Buy ↗
Even as SAVA stock whipsaws in both directions, Cassava's commitment to treating Alzheimer's disease remains as firm and steady as ever. 
Via InvestorPlace
News headline image
Cassava Is a Sell After Accusations of Data Manipulation ↗
After Cassava was accused of multiple improprieties for its star Simufilam drug, investors should sell the vast majority of their SAVA stock. 
Via InvestorPlace
News headline image
Short Squeeze Stocks: PROG, SAVA and 3 Others Experts Think Are Ready to Pop ↗
Fintel's list of short squeeze stocks to watch for this week is in. Here are the names that investors should be watching. 
Via InvestorPlace
News headline image
5 Short Squeeze Candidates To Watch: Progenity Tops List Again, Cassava Sciences Joins Following Short Report ↗
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: 
Via Benzinga
News headline image
81 Biggest Movers From Yesterday ↗
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares jumped 95.1% to close at $12.68 on Thursday after dropping over 10% on Wednesday. TDH Holdings, Inc. (NASDAQ: PETZ) jumped 79.8... 
Via Benzinga
News headline image
Why Did Cassava Sciences Stock Jump 49% Today? ↗
Journal of Neuroscience has informed Cassava Sciences Inc (NASDAQ: SAVA) that there is no evidence of data manipulation in an article published in July 2012... 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Nasdaq Jumps 150 Points; NeoPhotonics Shares Spike Higher ↗
Toward the end of trading Thursday, the Dow traded down 0.44% to 35,999.43 while the NASDAQ rose 0.97% to 15,964.55. The S&P also rose, gaining 0.30% to 4,674.44. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
Why Cassava Sciences Shares Are Rising ↗
Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading higher after a review by the Journal of Neuroscience showed there is no evidence of data manipulation in a 2012 company... 
Via Benzinga
News headline image
S&P 500, Nasdaq Nab More Intraday Highs, Dow Falls Triple Digits ↗
Stocks are mixed midday, with the Dow Jones Industrial Average down triple digits. 
Via Talk Markets
Topics Stocks
News headline image
SAVA Stock Alert: Why Cassava Sciences Is Rocketing 50% Higher Today ↗
Cassava Sciences just got good news. SAVA stock is soaring as the company celebrates the end of its manipulated data accusations. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Evaxion Biotech (NASDAQ:EVAX) stock moved upwards by 157.5% to $16.74 during Thursday's regular session. Evaxion Biotech's stock is trading at a volume of... 
Via Benzinga
News headline image
Mid-Day Market Update: Gold Rises 1.7%; Lightspeed Commerce Shares Plunge ↗
Midway through trading Thursday, the Dow traded down 0.25% to 36,068.78 while the NASDAQ rose 0.60% to 15,906.62. The S&P also rose, gaining 0.21% to 4,670.58. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
Cassava Stock Soars; Journal Finds No Proof Of Tampered Alzheimer's Data ↗
The journal that published a disputed paper from Cassava said Thursday it found no evidence of data manipulation, leading SAVA stock to soar. 
Via Investor's Business Daily
News headline image
Mid-Morning Market Update: Markets Mixed; Moderna Lowers Covid-19 Vaccine Sales Outlook ↗
Following the market opening Thursday, the Dow traded down 0.20% to 36,086.70 while the NASDAQ rose 0.83% to 15,942.06. The S&P also rose, gaining 0.40% to 4,679.39. The U.S.... 
Via Benzinga
Topics Stocks
News headline image
55 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares climbed 179% to $18.17 after dropping over 10% on Wednesday. NerdWallet, Inc. (NASDAQ: NRDS) jumped 60% to $28.86 after the... 
Via Benzinga
News headline image
Cassava Sciences Is on a Bumpy Road to Multibagger Status ↗
Based on analyst estimates for the next ten years, SAVA stock could be worth three times more if its Alzheimer's drug succeeds. 
Via InvestorPlace
News headline image
71 Biggest Movers From Yesterday ↗
Gainers Avis Budget Group, Inc. (NASDAQ: CAR) shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales... 
Via Benzinga
News headline image
SAVA Stock: 8 Things to Know as Cassava Sciences Rockets Higher ↗
As investors bet that Cassava Sciences is on the cusp of a breakthrough with its Alzheimer's treatment, SAVA stock is gaining. 
Via InvestorPlace
News headline image
What's Up With Cassava Sciences Flying Today? ↗
Cassava Sciences Inc (NASDAQ: SAVA) shares are trading up Tuesday as traders were able to push the stock higher. The stock has been trending on social media sites such... 
Via Benzinga
Artificial Intelligence Could Be About To Replace Your Doctor
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 2, 2021 – The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate. And... 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Cassava Stock Could Jump More Than 200 Times ↗
Cassava's Alzheimer's drug appears backed by strong data and plenty of public support. That's a winning combination for SAVA stock. 
Via InvestorPlace
News headline image
Cassava Sciences’ Stock Remains an Enigma ↗
Cassava Sciences has lost 26% for the month through Oct. 27. Entering October, SAVA stock looked to go on a big run. It did the opposite. 
Via InvestorPlace
News headline image
Buy SAVA Stock on Dips as its Phase 3 Trial Moves Along ↗
SAVA stock likely won't make another big move until Phase 3 trial data for Simulfilam comes in, so ease into it until then 
Via InvestorPlace
News headline image
SHAREHOLDER ALERT: Robbins LLP Investigates Cassava Sciences, Inc. (SAVA) on Behalf of Shareholders
From Robbins LLP
Via Business Wire
News headline image
SAVA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Cassava Sciences, Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
FINAL DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
38 39 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.